November 02, 2025

Get In Touch

Deepak Arora takes charge of Sanofi India as Managing Director

Mumbai:Sanofi India has announced the appointment of Deepak Arora as the Managing Director of the company, effective October 27, 2025, for a term of three years. The appointment, approved by the Board of Directors on the recommendation of the Nomination and Remuneration Committee, is subject to the approval of shareholders and the Central Government. In addition to his role as Managing Director, Arora has also been appointed as an Additional Director of the Company. Arora succeeds Rachid Ayari, who served as Interim Managing Director from July 21 to October 26, 2025. However, Rachid Ayari would continue to serve the Company in his role as Wholetime Director and Chief Financial Officer of the Company. Read also:Sanofi India appoints Rachid Ayari as Interim MD In this role, Deepak will define and drive the strategic visionfor India in alignment withSanofi's global strategy. He willalso spearhead strategic priorities to accelerate innovationand agility throughout the organization, while fosteringoperational excellence across all functions.

Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our Terms of Use, Privacy Policy, and Advertisement Policy.
For further details, please review our Full Disclaimer.

0 Comments

Post a comment

Please login to post a comment.

No comments yet. Be the first to comment!